Clinical Trials Logo

Unknown Primary Neoplasms clinical trials

View clinical trials related to Unknown Primary Neoplasms.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00353145 Completed - Clinical trials for Unknown Primary Neoplasms

Gemox as First and Second Line Therapy in Unknown Primary Cancer

Start date: February 2004
Phase: Phase 2
Study type: Interventional

Primary objectives: 1. To determine the overall tumor response rate with oxaliplatin in combination with gemcitabine (GEMOX) as first line and second line therapy in unknown primary cancer (UPC). 2. To determine the tolerability (toxicity) of this regimen in this patient population. Secondary objectives: 1. To determine the median overall survival (OS) and time to progression (TTP) for patients treated with this combination. 2. To determine the impact of this combination on quality of life (QOL) in this patient population.